Trevi Therapeutics (TRVI)
(Delayed Data from NSDQ)
$7.42 USD
+0.12 (1.64%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $7.42 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRVI 7.42 +0.12(1.64%)
Will TRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRVI
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
TRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study
What Makes Trevi Therapeutics (TRVI) a New Buy Stock
Other News for TRVI
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data
Trevi Therapeutics, Inc. (TRVI) Q2 2025 Earnings Call Transcript
TRVI Receives Updated Analyst Rating from Raymond James | TRVI Stock News
Trevi Therapeutics price target lowered by $2 at Raymond James, here's why
Needham Lowers Price Target for Trevi Therapeutics (TRVI) While Maintaining Buy Rating | TRVI ...